Optimer pays $20M to axe deal with Par

Optimer Pharma has regained the North American rights to Difimicin for Clostridium difficile-associated diarrhea from Par Pharmaceuticals. Optimer agreed to pay Par $20 million for the buy-back of Difimicin, which is in Phase IIb/III in North America. Optimer will also pay a $5 million milestone based on the successful commercialization of the therapy. Optimer was a 2006 Fierce 15 winner.

- see this press release from Par
- read the AP report for more

Related Article:
Optimer files IPO in bid to raise $86.3M. Report